Milademetan is under clinical development by Rain Oncology and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Milademetan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Milademetan overview

Milademetan is under development for the treatment of advanced solid tumors, liposarcoma, dedifferentiated liposarcoma, refractory or relapsed acute myeloid leukemia (AML),  pancreatic cancer, lung cancer, breast cancer, biliary tumor and malignant pleural mesothelioma (MPM). The drug candidate is administered orally as a capsule. The drug candidate acts by targeting murine double minute 2 (MDM2) protein.

It was also under development for acute lymphocytic leukemia (ALL), Merkel cell carcinoma, multiple myeloma, soft tissue sarcoma, lymphomas, chronic myelogenous leukemia (CML) and myelodysplastic syndrome.

Rain Oncology overview

Rain Oncology, formerly Rain Therapeutics, is a biotechnology company that discovers, develops and translates cancer therapies. It is investigating its lead product candidate milademetan, an oral small molecule, inhibitor of mouse double minute 2 (MDM2) to treat well-differentiated (WD) and dedifferentiated (DD) liposarcoma, Merkel cell carcinoma, amplified and advanced solid tumors. The company is also evaluating a RAD52 inhibiting program targeting homologous recombination deficiencies (HRD+) and loss of function of several pathway constituents including BRCA1/2, PALB2 in breast, prostate, pancreatic, ovarian and other tumors. Rain Oncology is headquartered in Newark, California, the US.

For a complete picture of Milademetan’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.